Mostly Markets
Subscribe
Markets
S&P 500 ▼ 1.82%Nasdaq ▼ 2.86%Dow ▼ 1.09%Russell 2000 ▼ 1.66%10-year 4.93%Oil ▲ 0.93%Gold ▼ 3.63%Bitcoin ▲ 1.13%
Newest story
Stocks/Health Care/Pharmaceuticals

Johnson & JohnsonJNJ

Pharmaceuticals · New Brunswick, New Jersey · In the S&P 500
Solid businessPricier than peers
$273.20−0.73%After hours: $273.48 (+0.10%)At the close, 30 Oct · Prices from CNBC, may be delayed
▲ 46.4% over 1 year
Johnson & Johnson over 1 yearDaily close, $, to 30 Oct 2026
$200$225$250Nov2026MarMayJulSep$273.20$200$250NovMarJul$273.20
Source: Nasdaq daily closes
Market value$658B
Price to earnings41.5x
Forward P/E25.1x
Dividend yield1.96%
Year to date+32.0%
One year+46.4%
Next earningsNot scheduled
SectorHealth Care
52-week range (closes)
$186.00$278.43

The latest on Johnson & Johnson

Our stories first, then the headlines that could move it, newest first.

We haven't written about Johnson & Johnson yet. Follow it, and its first story will show under My stocks.

Quality and valuation

How Johnson & Johnson compares with other health care stocks. A description, not a recommendation.

Johnson & Johnson and 4 pharmaceuticals peers. Across: valuation (P/E) against the sector. Up: business quality against the sector. Hover or tap a logo for its numbers.

Business quality: about averageValuation: pricier than most

An average business among health care companies, priced above most of them.

Johnson & Johnson trades at 25.1 times the next 12 months of expected earnings, against a median of 19.1x for the 65 health care stocks we cover. The quality score blends where it ranks on revenue growth, gross margin, operating margin and free-cash-flow margin (net margin for banks and insurers) over the last 12 months, from SEC filings.

  • Revenue grew slower than the sector median: +7.8% vs +7.8%
  • Keeps more of each sale (gross margin): 67.6% vs 65.3%
  • Turns more of its sales into cash: 20.7% vs 15.9%
  • Keeps more of its revenue as profit (net margin): 16.2% vs 9.7%
JNJ trades at 25.1x forward earnings, above the sector medianForward p/e, Pharmaceuticals peers
BMY10.5xPFE11.1xNVO12.2xNVS17.0xAZN17.5xMRK18.1xJNJ25.1xLLY36.3xSector median 19.1xBMY10.5xPFE11.1xNVO12.2xNVS17.0xAZN17.5xMRK18.1xJNJ25.1xLLY36.3xSector median 19.1x
Source: CNBC quotes; Mostly Markets
At 41.5x earnings, JNJ is pricier than its average since Oct 2024Price over the last 12 months of reported (GAAP) diluted EPS
P/EUsual range (±1 s.d.)
20x30xAverage 23.8x2025202641.5x20x30xAverage 23.8x2025202641.5x
Source: Nasdaq prices; SEC filings

Financials

From Johnson & Johnson's SEC filings, through the quarter ending 27 Sep 2026. Hover or tap a bar for its value.

Revenue grew 5.9% from a year earlierQuarterly revenue, $bn, latest Q3 ’26
$0bn$10bn$20bnQ4 ’24Q2 ’25Q4 ’25$25.4bnQ3 ’26$0bn$10bn$20bnQ4 ’24Q2 ’25Q4 ’25$25.4bnQ3 ’26
Source: SEC filings
Growth slowed to +5.9% last quarterRevenue growth, year on year, %
0%2%5%8%Q4 ’24Q2 ’25Q4 ’255.9%Q3 ’260%5%Q4 ’24Q2 ’25Q4 ’255.9%Q3 ’26
Source: SEC filings
Free cash flow was $20.6 billion over 12 monthsQuarterly free cash flow (operating cash flow minus capex), $bn
$0bn$2bn$5bn$8bnQ4 ’24Q2 ’25Q4 ’25$6.4bnQ3 ’26$0bn$5bnQ4 ’24Q2 ’25Q4 ’25$6.4bnQ3 ’26
Source: SEC filings
Diluted EPS was $0.09 last quarterQuarterly diluted earnings per share, $
$0$2$4Q4 ’24Q2 ’25Q4 ’25$0.09Q3 ’26$0$2$4Q4 ’24Q2 ’25Q4 ’25$0.09Q3 ’26
Source: SEC filings
Last 12 monthsJNJSector median
Revenue growth+7.8%+7.8%
Gross margin67.6%65.3%
Free cash flow margin20.7%15.9%
Price to earnings41.5x30.2x

Similar companies

Pharmaceuticals, by market value.

CompanyPriceTodayYTDValue
LLYEli Lilly$1,417.54+3.19%+31.9%$1.33T
MRKMerck$149.52+2.18%+42.0%$369B
NVSNovartis$160.79−0.19%+16.6%$327B
AZNAstraZeneca$186.65+7.02%+6.4%$290B
PFEPfizer$30.52+1.90%+22.6%$174B
NVONovo Nordisk$40.00+2.20%−21.4%$136B
BMYBristol Myers Squibb$62.48+1.78%+15.8%$128B
ZTSZoetis$79.72+1.85%−36.6%$32.94B